Phase II study to determine response rate, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of treatment with the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 (matuzumab) in patients with recurrent cervical cancer
暂无分享,去创建一个
W. M. Smit | M. Gore | R. Kimmig | S. Kuemmel | J. Blohmer | S. Kaye | R. Verheijen | L. Massuger | A. Bois | C. Deubelbeiss